-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
New findings published February 15, 2022 in the journal JAMA Network Open confirm that the pandemic actually delays breast cancer diagnoses
While the total number of diagnoses in 2019 and 2020 were roughly similar, there was a significant difference in the percentage of breast cancer stage I diagnoses versus stage IV diagnoses
For example, in 2019, 63.
(Most cancers are assigned a stage at the time of diagnosis, from the first stage, when the malignancy is confined to its location of origin, to the fourth stage, when the cancer has spread to other organs or parts of the body, with increasing difficulty in treatment and cure
A similar trend was found in the colorectal cancer patients studied, albeit to a slightly lower degree than in breast cancer patients
"For breast cancer at least, these data show a continuing trend," said first author Jade Zifei Zhou, PhD, a clinical investigator in hematology and oncology at the UC San Diego School of Medicine
The researchers noted several limitations of the study
"Cancer screening is critical for the early detection of cancers, especially in colorectal and breast cancers, many of which are treatable and curable," said senior author Kathryn Ann King, a medical oncologist
“There is growing concern that one impact of the pandemic is that more patients are being diagnosed for the first time with an advanced, incurable disease
Jade Zifei Zhou, Shelly Kane, Celia Ramsey, Melody Akhondzadeh, Ananya Banerjee, Rebecca Shatsky, Kathryn Ann Gold.
